Article

Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population

2024-10-08

Abstract excerpt

<h4>Background</h4> introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and/or HRD-positive EOC patients in real-world practice setting. <h4>Patients and methods</h4> we enrolled patients with FI...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b8d1079b-e93f-50f3-ac92-1fe4aacb5935
DOI: 10.1101/2024.10.07.24315067

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched populationDOI 10.1101/2024.10.07.24315067Read

Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.Semantic proximity Read

Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.Semantic proximity Read

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studySemantic proximity Read

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer.Semantic proximity Read

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapySemantic proximity Read

Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India.Semantic proximity Read

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trialsSemantic proximity Read

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on the Chemotherapy in Clinical PracticeSemantic proximity Read

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSASemantic proximity Read

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian CancerSemantic proximity Read

Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.Semantic proximity Read